🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.3553
-0.0011 (-0.31%)
Nov 18, 2026, 4:00 PM EST - Market closed

Rein Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.1810.913.8611.369.689.6
Research & Development
13.0911.0314.253.9917.9717.01
Operating Expenses
22.2621.9328.1115.3527.6526.61
Operating Income
-22.26-21.93-28.11-15.35-27.65-26.61
Interest & Investment Income
--0.70.6--
Other Non Operating Income (Expenses)
0.540.05-0.02-0.090.32-0.01
EBT Excluding Unusual Items
-21.73-21.88-27.43-14.84-27.33-26.62
Merger & Restructuring Charges
----0.93--
Gain (Loss) on Sale of Assets
---0.04-0.07
Asset Writedown
-28.7-28.7-37---
Other Unusual Items
-----0.39
Pretax Income
-50.43-50.58-64.43-15.73-27.33-26.16
Income Tax Expense
-0.71-0.71-1.54---
Net Income
-49.72-49.87-62.88-15.73-27.33-26.16
Net Income to Common
-49.72-49.87-62.88-15.73-27.33-26.16
Net Income Growth
------
Shares Outstanding (Basic)
542518554
Shares Outstanding (Diluted)
542518554
Shares Change
128.93%41.84%290.09%1.31%2.23%154.70%
EPS (Basic)
-0.92-1.96-3.51-3.42-6.02-5.89
EPS (Diluted)
-0.93-1.96-3.51-3.42-6.02-5.89
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-22.55-19.36-22.29-19.81-24.87-23.91
Free Cash Flow Per Share
-0.42-0.76-1.24-4.31-5.48-5.38
EBITDA
-22.26-21.93-28.05-15.23-27.48-26.48
D&A For EBITDA
000.060.120.170.12
EBIT
-22.26-21.93-28.11-15.35-27.65-26.61
SEC Filings: 10-K · 10-Q